Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CardiolRx in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
NCT04615949Phase 3Terminated
- Sponsor
- Cardiol Therapeutics Inc.
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of cannabidiol in coronavirus disease 2019 (COVID-19), sponsored by Cardiol Therapeutics Inc.. Started Apr 2021; status: terminated.
02
Drugs
cannabidiol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04615949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615949.